PR Newswire BiotechOriginal article
Landmark CLiMB Study Demonstrates Superior Sensitivity of HelioLiver™, a Multi-Analyte Blood Test, Over Ultrasound for Early Detection of Hepatocellular Carcinoma
Data ReadoutpositiveHelioLiver™Positive
AI Analysis
Summary
Helio Genomics' prospective multicenter CLiMB trial demonstrates that HelioLiver™, a multi-analyte blood test, detects hepatocellular carcinoma earlier and with superior sensitivity compared to abdominal ultrasound in high-risk cirrhosis patients.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
HelioLiver™ demonstrates superior sensitivity over abdominal ultrasound for early detection of hepatocellular carcinoma in high-risk patients with cirrhosis
Importance:7/10
Sentiment:
0.80
early cancer detectionhepatocellular carcinomablood testdiagnosticprospective multicenter trialCLiMB study
Related Companies
Read the original article
Published by PR Newswire Biotech on May 6, 2026 1:20 PM